AI fertility start-up bags US$2m in funding to boost IVF outcomes

The Polish AI fertility start-up MIM Fertility has raised US$2m in funding in a bid to boost IVF success rates.

MIM Fertility, a spin-off of the Faculty of Mathematics, Informatics and Mechanics of the University of Warsaw, uses machine learning and deep learning algorithms to develop new reproductive medicine solutions.

The technologies, aimed at increasing people’s chances of becoming parents, promise to improve diagnosis and treatment outcomes, save professionals time and reduce healthcare costs.

The funding round, led by Warsaw-based Tangent Line Ventures and Peleton, is hoped to enable the start-up to “refine” its existing technologies, develop new functionalities and expand its global footprint.

“The investment from Tangent Line and Peleton is a significant boost for our company and a validation that we are moving in the right direction,” said Piotr Wygocki, co-founder of MIM Fertility.

Ula Sankowska, co-founder of MIM Fertility, said: “We are excited about the opportunities this investment opens up for us, particularly in scaling our solutions and extending our presence in the global infertility treatment market.”

Infertility is a challenge both in Poland and globally, impacting the lives of millions of couples. According to the World Health Organization (WHO), it affects around 17 per cent of couples worldwide, translating to about 48-186 million people.

Infertility is a complex phenomenon that can stem from various causes in both women and men. Medical solutions, such as IVF, offer hope for many couples. However, the cost and accessibility of these procedures mean that many are left unable to access treatment.

Through its AI-driven technologies, MIM Fertility aims to help more couples fulfil their dream of parenthood. Its products, EMBRYOAID and FOLLISCAN, mark a new generation of tools supporting experts in the identification and analysis of ovarian follicles and embryo assessment.

The company is planning to use the funding to intensify research and development and continue its collaboration with institutions and experts in the field of reproductive medicine.

Piotr Pietrzak from Tangent Line Ventures, said: “MIM Fertility’s approach to using AI to enhance infertility treatment outcomes is precisely what modern medicine needs.

“We are impressed by the innovation and potential of the company and their commitment to addressing real issues in reproductive health.”